U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H53NO14.3H2O
Molecular Weight 861.9251
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DOCETAXEL

SMILES

O.O.O.[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C6=CC=CC=C6

InChI

InChIKey=XCDIRYDKECHIPE-QHEQPUDQSA-N
InChI=1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1

HIDE SMILES / InChI
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C43H53NO14
Molecular Weight 807.8792
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including

Docetaxel was protected by patents (U.S. patent and European patent) which were owned by Sanofi-Aventis, and so was available only under the Taxotere brand name internationally. The European patent expired in 2010. Docetaxel is a clinically well-established anti-mitotic chemotherapy medication used for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarcinoma and head and neck cancer. Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: docetaxel cannot cross the blood–brain barrier and control metastatic foci

Originator

Approval Year

1996
225
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

1996
Primary
Approved
8429
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

1996
Primary
Approved
8429
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

1996
Primary
Approved
8429
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

1996
Primary
Approved
8429
TAXOTERE

Approved Use

INDICATIONS & USAGE Docetaxel injection concentrate is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC (1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer (1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN (1.5) 1.1 Breast Cancer Docetaxel injection concentrate is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel injection concentrate in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer Docetaxel injection concentrate as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel injection concentrate in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel injection concentrate in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel injection concentrate in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
742 nM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17956601
20 mg/m² 1 times / week multiple, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3737 nM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17956601
100 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1284 nM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17956601
20 mg/m² 1 times / week multiple, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
5562 nM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17956601
100 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.99 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17956601
20 mg/m² 1 times / week multiple, intravenous
dose: 20 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.74 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/17956601
100 mg/m² 1 times / 3 weeks multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.1 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022234s000lbl.pdf
100 mg/m² 1 times / hour multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022234s000lbl.pdf
100 mg/m² 1 times / hour multiple, intravenous
dose: 100 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DOCETAXEL plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
75 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/8761385
unhealthy, 51 years (range: 36 - 65 years)
n = 39
Health Status: unhealthy
Condition: advanced breast cancer:
Age Group: 51 years (range: 36 - 65 years)
Sex: F
Population Size: 39
Sources:
https://pubmed.ncbi.nlm.nih.gov/8761385
Disc. AE: Fluid retention...
AEs leading to
discontinuation/dose reduction:
Fluid retention (16 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/8761385
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
DLT: Fatigue, Asthenia...
Other AEs: Nail toxicity, Alopecia...
Dose limiting toxicities:
Fatigue (grade 3-4, 2 patients)
Asthenia (grade 3-4, 2 patients)
Skin toxicity (grade 3-4, 1 patient)
Diarrhea (grade 3-4, 1 patient)
Other AEs:
Nail toxicity (grade 3-4, 1 patient)
Alopecia (grade 2, 1 patient)
Leukopenia (grade 3, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
52 mg/m2 1 times / week multiple, intravenous
Dose: 52 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 52 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 3
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
DLT: Fatigue, Asthenia...
Dose limiting toxicities:
Fatigue (grade 3-4, 3 patients)
Asthenia (grade 3-4, 3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Other AEs: Neutropenia, Asthenia...
Other AEs:
Neutropenia (severe)
Asthenia (mild)
Epidermal and dermal conditions
Paresthesia (mild)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Other AEs: Neutropenia, Asthenia...
Other AEs:
Neutropenia (severe)
Asthenia (mild)
Epidermal and dermal conditions
Paresthesia (mild)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Disc. AE: Hypersensitivity...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (severe)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
100 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Other AEs: Hepatotoxicity...
Other AEs:
Hepatotoxicity (grade 5)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Fluid retention 16 patients
Disc. AE
75 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 75 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 75 mg/m2, 1 times / 3 weeks
Sources:
https://pubmed.ncbi.nlm.nih.gov/8761385
unhealthy, 51 years (range: 36 - 65 years)
n = 39
Health Status: unhealthy
Condition: advanced breast cancer:
Age Group: 51 years (range: 36 - 65 years)
Sex: F
Population Size: 39
Sources:
https://pubmed.ncbi.nlm.nih.gov/8761385
Alopecia grade 2, 1 patient
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Leukopenia grade 3, 2 patients
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Nail toxicity grade 3-4, 1 patient
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Diarrhea grade 3-4, 1 patient
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Skin toxicity grade 3-4, 1 patient
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Asthenia grade 3-4, 2 patients
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Fatigue grade 3-4, 2 patients
DLT
43 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 43 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 43 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 10
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 10
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Asthenia grade 3-4, 3 patients
DLT
52 mg/m2 1 times / week multiple, intravenous
Dose: 52 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 52 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 3
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Fatigue grade 3-4, 3 patients
DLT
52 mg/m2 1 times / week multiple, intravenous
Dose: 52 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 52 mg/m2, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
unhealthy, 58 years (range: 41-81 years)
n = 3
Health Status: unhealthy
Condition: Advanced Refractory Cancer
Age Group: 58 years (range: 41-81 years)
Sex: M+F
Population Size: 3
Sources:
https://pubmed.ncbi.nlm.nih.gov/9626217
Epidermal and dermal conditions
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Asthenia mild
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Paresthesia mild
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Neutropenia severe
150 mg/m2 single, intravenous
Overdose
Dose: 150 mg/m2
Route: intravenous
Route: single
Dose: 150 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Epidermal and dermal conditions
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Asthenia mild
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Paresthesia mild
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Neutropenia severe
200 mg/m2 single, intravenous
Overdose
Dose: 200 mg/m2
Route: intravenous
Route: single
Dose: 200 mg/m2
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Hypersensitivity severe
Disc. AE
60 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 60 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 60 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Hepatotoxicity grade 5
100 mg/m2 1 times / 3 weeks multiple, intravenous
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737
substrate
1037
substrate
1217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP3A
191

P-gp
1537

CYP1A2
1054

CYP2C8
693

CYP2E1
667

CYP3A5
395

OATP1B3
350

MRP2
205

OAT2
115

OATP1A2
62

OATP1B1
406

OAT1
326

OAT3
339

OCT1
327

OCT2
355

OCT3
80

MRP4
77

BCRP
561
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A
191
 major
likely
Comment: In vivo studies showed that the exposure o f docetaxel increased 2.2-fold when it was coadministered with ketoconazole, a potent inhibitor o f CYP3A4. Protease inhibitors, particularly ritonavir, may increase the exposure o f docetaxe
Page: 12.0
BCRP
561
 no
CYP1A2
1054
 no
CYP2C8
693
 no
CYP2C9
1037
 no
CYP2D6
1217
 no
CYP2E1
667
 no
MRP4
77
 no
OAT1
326
 no
OAT3
339
 no
OATP1B1
406
 no
OCT1
327
 no
OCT2
355
 no
OCT3
80
 no
CYP3A5
395
 yes
MRP2
205
 yes
OAT2
115
 yes
OATP1A2
62
 yes
OATP1B3
350
 yes
P-gp
1537
 yes
CYP3A4
1737
 yes
yes (co-administration study)
Comment: The effect o f ketoconazole (a strong CYP3A4 inhibitor) on the pharmacokinetics o f docetaxel was investigated in 7 cancer patients. Patients were randomized to receive either docetaxel (100 mg/m2 intravenous) alone or docetaxel (10 mg/m2 intravenous) in combination with ketoconazole (200 mg orally once daily for 3 days) in a crossover design with a 3-week washout period. The results o f this study indicated that the mean dose-normalized AUC o f docetaxel was increased 2.2-fold and its clearance was reduced by 49% when docetaxel was coadministration with ketoconazole
Page: 13.0
PubMed

PubMed

TitleDatePubMed
Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
2004 Dec 15
Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
2005
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
2005 Aug
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
2005 Dec
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
2005 Dec 15
Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy.
2005 Feb
Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory.
2005 Jan
Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.
2005 Jul
HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
2005 Jun 1
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
2005 Jun 15
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
2005 Jun 20
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
2005 May
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
2005 May
Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
2005 May-Jun
Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
2005 Nov 2
PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.
2005 Oct 15
[Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere].
2005 Sep
Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells.
2005 Sep 1
Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
2005 Sep 15
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
2005 Sep 20
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
2006 Apr
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
2006 Aug
Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
2006 Aug
Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
2006 Aug 15
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
2006 Feb 23
Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines.
2006 Jan 15
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
2006 Jan 15
Vitamin D compounds: clinical development as cancer therapy and prevention agents.
2006 Jul-Aug
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
2006 Jun 5
Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.
2006 Mar-Apr
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
2006 May
Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB.
2006 May
Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer.
2006 Oct 1
Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
2006 Oct 1
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
2007
Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
2007 Aug
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
2007 Aug
Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.
2007 Aug
Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2.
2007 Feb
Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance.
2007 Feb
Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
2007 Feb
Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway.
2007 Feb 15
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells.
2007 Jan
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
2007 Jun
Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3.
2007 Mar 8
Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
2007 May-Jun
Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
2007 Oct
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
2007 Sep 1
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
2008 Feb
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
2008 Feb
Patents

Patents

JP2001247521A
3
JP2001519784A
3
JP2002516910A
10
JP2003055208A
3
JP2003201287A
3
JP2003512301A
15
JP2005508920A
3
JP2005523278A
25
JP2006505545A
3
JP2006507308A
13
JP2006508958A
3
JP2007504131A
12
JP2007509978A
4
JP2008500430A
7
JP2008508853A
10
JP2008525588A
5
JP2009507027A
3
JP2009519341A
24
JP2010100628A
3
JP2011528326A
17
JP2011529042A
5
JP4656725B2
9
JP4722295B2
104
JP4754967B2
7
JP4827411B2
3
JPH10203975A
3

Sample Use Guides

In Vivo Use Guide
Breast Cancer: 60 mg/m2 to 100 mg/m2 administered intravenously over 1 hour every 3 weeks. Non-Small Cell Lung Cancer: 75 mg/m2 administered intravenously over 1 hour every 3 weeks. Prostate Cancer: 75 mg/m2 every 3 weeks as a 1 hour intravenous infusion. Gastric Adenocarcinoma: 75 mg/m2 as a 1 hour intravenous infusion, followed by cisplatin 75 mg/m2 , as a 1 to 3 hour intravenous infusion (both on day 1 only), followed by fluorouracil 750 mg/m2 per day given as a 24-hour continuous intravenous infusion for 5 days, starting at the end of the cisplatin infusion Head and Neck Cancer: Induction chemotherapy followed by radiotherapy: For the induction treatment of locally advanced inoperable SCCHN, the recommended dose of TAXOTERE (docetaxel) is 75 mg/m2 as a 1 hour intravenous infusion followed by cisplatin 75 mg/m2 intravenously over 1 hour, on day one, followed by fluorouracil as a continuous intravenous infusion at 750 mg/m2 per day for five days. This regimen is administered every 3 weeks for 4 cycles. Following chemotherapy, patients should receive radiotherapy.
Route of Administration: Intravenous
In Vitro Use Guide
The in vitro antiproliferative effect of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin was assessed in a range of human tumour types, including 25 tumour cell lines and 35 primary cultures. In all comparisons docetaxel and paclitaxel were much more potent than cisplatin with IC50 values of the taxoids being in the nanomolar range. Docetaxel generally was two- to four-fold more cytotoxic than paclitaxel. The sensitivity profile of the cell lines, which was based on the IC50 values, indicated a certain degree of cross-sensitivity between paclitaxel and docetaxel (linear regression analysis; r = 0.73, p < 0.001
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:26:50 GMT 2023
Edited
by admin
on Fri Dec 15 15:26:50 GMT 2023
Record UNII
15H5577CQD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DOCETAXEL
EMA EPAR   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TAXOTERE
Brand Name English
(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate
Common Name English
DOCETAXEL (AS TRIHYDRATE)
Common Name English
DOCETAXEL [VANDF]
Common Name English
DOCETAXEL HYDRATE [JAN]
Common Name English
Docetaxel [WHO-DD]
Common Name English
RP 56976
Code English
DOCETAXEL [USP-RS]
Common Name English
DOCETAXEL [USAN]
Common Name English
DOCETAXEL TRIHYDRATE
EP   MI  
Common Name English
DOCETAXEL [USP MONOGRAPH]
Common Name English
DOCETAXEL [EMA EPAR]
Common Name English
DOCETAXEL [USP IMPURITY]
Common Name English
DOCETAXEL TRIHYDRATE [MI]
Common Name English
DOCETAXEL TRIHYDRATE [EP MONOGRAPH]
Common Name English
DOCETAXEL [EP MONOGRAPH]
Common Name English
XRP6976
Code English
RP-56976
Code English
DOCETAXEL [ORANGE BOOK]
Common Name English
DOCETAXEL HYDRATE
JAN  
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67437
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS DOCEFREZ(WITHDRAWN: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS DOCETAXEL TEVA (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS DOCETAXEL KABI (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS TAXESPIRA (AUTHORISED: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
LIVERTOX NBK548899
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
NDF-RT N0000175592
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
WHO-VATC QL01CD02
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS TAXOTERE (AUTHORIZED: STOMACH NEOPLASMS)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS DOCETAXEL WINTHROP (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS DOCETAXEL MYLAN (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS DOCETAXEL TEVA PHARMA(AUTHORIZED: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS DOCETAXEL ACCORD (AUTHORIZED: BREAST, PROSTETIC, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
EMA ASSESSMENT REPORTS TAXOTERE (AUTHORIZED: BREAST, PROSTETIC, STOMACH, HEAD AND NECK NEOPLASMS, CARCINOMA,NON-SMALL-CELL-LUNG, ADENOCARCINOMA)
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
WHO-ATC L01CD02
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
FDA ORPHAN DRUG 649918
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
NCI_THESAURUS C1490
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
Code System Code Type Description
CHEBI
4672
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
EVMPD
SUB25446
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
MESH
C067311
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
USAN
FF-68
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
EPA CompTox
DTXSID80872444
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
MERCK INDEX
m4712
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
DOCETAXEL
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
PUBCHEM
148123
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
RS_ITEM_NUM
1224551
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL92
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
RXCUI
72962
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY RxNorm
LACTMED
Docetaxel
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
IUPHAR
6809
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
CHEBI
59809
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
SMS_ID
100000089469
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
NCI_THESAURUS
C1526
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
DRUG CENTRAL
939
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
DAILYMED
15H5577CQD
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
CAS
148408-66-6
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
DRUG BANK
DB01248
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
FDA UNII
15H5577CQD
Created by admin on Fri Dec 15 15:26:50 GMT 2023 , Edited by admin on Fri Dec 15 15:26:50 GMT 2023
PRIMARY
Related Record Type Details
Structure of DOCETAXEL ANHYDROUS
PARENT -> SALT/SOLVATE
Structure of DOCETAXEL ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Structure of DOCETAXEL ANHYDROUS
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of DOCETAXEL ANHYDROUS
ANHYDROUS->SOLVATE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Related Record Type Details
Structure of 2'-O-(4-DIETHYLAMINOBUTANOYL)DOCETAXEL
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of 4-EPI-6-OXODOCETAXEL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4-EPIDOCETAXEL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-O-DESBENZOYL-2-O-TIGLYLDOCETAXEL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4-EPIDOCETAXEL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 6-OXODOCETAXEL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 6-OXODOCETAXEL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of DOCETAXEL ANHYDROUS
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966